Anixa Biosciences (NASDAQ:ANIX) released its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports.
NASDAQ:ANIX opened at $4.33 on Friday. Anixa Biosciences has a 12-month low of $1.70 and a 12-month high of $8.09. The company has a market cap of $136.10 million, a price-to-earnings ratio of -3.83 and a beta of 1.41. The business has a fifty day moving average of $4.32.
A number of research firms recently weighed in on ANIX. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Anixa Biosciences in a report on Friday, May 21st. Aegis reissued a “buy” rating on shares of Anixa Biosciences in a research note on Monday, February 15th. Finally, Zacks Investment Research cut Anixa Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 27th.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.
Further Reading: Market Indexes
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.